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Abstract
Background: The BED Capture Enzyme Immunoassay, believed to distinguish recent HIV infections, is being used to
estimate HIV incidence, although an important property of the test – how specificity changes with time since infection – has
not been not measured.
Methods: We construct hypothetical scenarios for the performance of BED test, consistent with current knowledge, and explore
how this could influence errors in BED estimates of incidence using a mathematical model of six African countries. The model is
also used to determine the conditions and the sample sizes required for the BED test to reliably detect trends in HIV incidence.
Results: If the chance of misclassification by BED increases with time since infection, the overall proportion of individuals
misclassified could vary widely between countries, over time, and across age-groups, in a manner determined by the
historic course of the epidemic and the age-pattern of incidence. Under some circumstances, changes in BED estimates over
time can approximately track actual changes in incidence, but large sample sizes (50,000+) will be required for recorded
changes to be statistically significant.
Conclusions: The relationship between BED test specificity and time since infection has not been fully measured, but, if it
decreases, errors in estimates of incidence could vary by place, time and age-group. This means that post-assay adjustment
procedures using parameters from different populations or at different times may not be valid. Further research is urgently
needed into the properties of the BED test, and the rate of misclassification in a wide range of populations.
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Introduction
To date, HIV prevalence has been the main measure used in
monitoring HIV epidemics, but it is neither timely nor easily
interpreted, especially since antiretroviral treatment can increase
prevalence without concomitant increases in the spread of the
virus [1,2,3,4]. A measure of incidence would provide a better tool
to plan and evaluate HIV programmes [5], but cohort studies are
prohibitively expensive and often unrepresentative. Mathematical
models provide an indirect way to estimate incidence [6,7], but a
practical and valid method of measuring incidence from cross-
sectional surveys would be ideal, and a number of assays have
been developed in the hope of serving this purpose [8].
The underlying principle of these assays is that the immuno-
logical response to HIV evolves over the first months of infection,
and by measuring the quantity, proportion or avidity of HIV
antibody, recent infections can be discriminated from older ones.
The most widely used of these assays is the BED capture enzyme
immunosorbent assay (‘BED test’), in which the optical density
varies according to proportion of IgG that is anti-HIV antibody
[9]. A recent infection is usually defined as one for which the
optical density of the test is less than 0.8, which corresponds to
approximately 150–187 days after seroconversion [10,11,12] – in
this article, this period is denoted V. Assuming that all (or a known
proportion of) the detected recent infections have occurred within
a period V preceding the survey, the number of incidence infection
occurring in the last year can be estimated [10].
BED-derived estimates of incidence have been compared with
gold-standard measures of incidence in a range of settings [10,13].
BED estimates are typically substantially too high [13,14], leading
to calls for caution in the use and interpretation of the test [15]. It
has become clear that this is because the test misclassifies some
individuals infected for more than one year as being recently
infected [14]. Current guidelines [16] support using a post-assay
correction calculation, using an empirical measurement of the
fraction of individuals infected for more than a year are
misclassified as recent (labelled e by Hargrove et al. [14]). It
follows that the success of this correction procedure will be
dependent on the accuracy of the value used for e [17].
e has been measured in a small number of populations
[13,14,17,18,19] and values vary between 1.7% (South Africa
[17]) and 27% (Rwanda and Zambia [13]). Estimating incidence
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population to estimate incidence in another, had lead to seemingly
unrealistically high estimates of incidence estimates in Cote
d’Ivoire [18], South Africa [17,20], Uganda [21] and Kenya
[22], and unrealistically low estimates in Kwazulu-Natal in South-
Africa [17]. There have been calls for further studies measuring e
[15,16], but if it is found that it varies widely, necessitating
measurement in every population in which the BED test is used,
then the usefulness of the BED test would be limited.
One key property of the BED test is the relationship between
the chance that an infection is misclassified as recent (Proportion
False Positive), and the time since infection (denoted PFP(t)). (Note
that the eof Hargrove et al. is not time-variant.) This property has
not been fully quantified, but there is mounting evidence that the
chance of misclassification is higher for those with advanced
infections. One reason is that the proportion of IgG that is HIV
antibody could fall below the threshold in response to either the
onset of opportunistic infections or treatment with antiretroviral
therapy [23,24,25]. In small prospective studies, some individuals
have been observed to revert to false positive result after months of
infection. Treatment initiation also leads to regression past/
towards the optical density cut-off [13,24,25]. Furthermore, a new
study shows that the chance of misclassification is much higher for
individuals indicated to start therapy and with low CD4 cell
counts, than those with established infection but without
symptoms [26]. In one study of post-partum women, the rate of
misclassification was not associated with age or CD4 cell count
(although there were low numbers of women with the lowest CD4
counts) [14], but this is not necessarily inconsistent with an up-turn
in PFP many years after infection (fertility declines steeply with
time infected with HIV [27], and most women in this study would
probably have been infected in the previous few years). Another
reason why misclassification could increase with time since
infection would be if the individuals with fully developed
immune-responses that are misclassified as recent live for longer
than others. This is supported by observations of elite viral
suppressors, that live for longer than those with higher viral loads,
being more often misclassified as recent than others [23,28].
To explore the influence that the relationship between PFP and
time since infection could have on e and ‘corrected’ BED estimates
of incidence, we constructed a mathematical model describing
HIV incidence, prevalence and the distribution of time since
infection across a population, and represented a range of
epidemics from six countries in sub-Saharan Africa (Kenya,
Lesotho, Mozambique, Nigeria, Uganda and Zambia). We
evaluated e in the different settings, and compared the simulated
incidence rates with the corresponding corrected BED-derived
estimates that would arise from surveys of the modelled
population, making alternative assumptions about how the PFP
varies over longer times since infection. We then explored how
reliably the BED test could track changes in incidence over time
by modelling an instantaneous change in incidence by a factor 0.5,
0.75, 1.0, 1.25 or 1.5. Finally we calculated the required sample
sizes in the surveys for a trend to be statistically significant.
Methods
A system of partial differential equations was used to track
numbers of susceptible and infected individuals in each sex and
age-group over time (Text S1). Incidence rates in six African
countries across all ages, 1985–2005, were calculated using
Spectrum software [29] and UNAIDS estimates of prevalence
[1], and were input to the model (Figure S1). The relative rate of
incidence according to sex and age groups was based on recent
empirical observations in eastern Zimbabwe [30] (Table S1) and it
was assumed that this pattern is approximately constant over time.
Net survival with HIV is assumed to be Weibull distributed and
dependent on the age at infection [31] (Table S2). Background
mortality rates (from causes other than HIV) and fertility rates are
based on observation in African population in the pre-AIDS era
[32] (Table S3).
To understand the properties of the BED test that determine the
accuracy of derived incidence estimates, we define the ‘BED
response function’ x w ðÞas the fraction of blood samples from
individuals who are alive and have been infected for w years that
the BED test classifies/misclassifies as ‘recent’. As described above,
the period after infection for which infections should be classified
as recent by a perfect test is V. In this way, we write that the
sensitivity of the test is: r w ðÞ ~x w ðÞ Vvw, and the specificity of
the test to infections that are w years old as:
r w ðÞ ~1{x w ðÞ wwV. (For complete definitions of sensitivity
and specificity using this notation, see Appendix.) The BED
response function can be approximately parameterised from data
for the first two years after infection (Figure 1). V is taken to be 0.5
years; r 0vwƒV ðÞ ~0:8, and r Vvwƒ2V ðÞ ~0:2 (i.e. ‘recent’
infections are less than 0.5 years old, and sensitivity to recent
infections is equal to 1-specificity for infections between 0.5 and
1.0 years old [14]). [10,14]. Beyond this time, PFP as a function of
time since infection has not been directly observed, so we construct
two hypothetical scenarios (Figure 1); it stays constant over time
since infection at 5% (as implied by Hargrove et al. [14]: Scenario A),
or it increases over time since infection to 50% after 20 years
(Scenario B).
In the model analyses, the distribution of time since infection for
the people living with HIV is described with respect to age and
time for each of the six African countries considered. The extent of
potential misclassification by the BED test was quantified as the
proportion of individuals infected with HIV for at least one year
that would be wrongly classified as recent infections, correspond-
ing to the value of e in Hargrove et al. The ‘‘Spectrum incidence
rate’’ was compared with the estimate from the BED test, making
alternative assumptions about the BED response function, and
using the post-assay correction formulae assuming a constant value
of e~5%. We note that the accuracy of the Spectrum incidence
estimates compared to the real world is not known, but that, within
this modelling exercise, they do represent the gold-standard
against which to compare the corresponding simulation of the
BED estimates. Indicative sample sizes required to statistically
detect changes were calculated naively using standard formulae for
differences in proportions [33].
Results
Comparing the distribution of time since infection for those
HIV infected by 1995 and ten years later, in 2005, there is a
general increase in the proportion infected for a long time, but this
varies greatly by country and age-group (Figure 2). Across
countries, recent infections are more frequent in countries that
have experienced recent epidemic growth (e.g. Mozambique) and
late infections are more frequent following epidemic stabilisation
and decline (e.g. Uganda and Kenya). Early in the epidemic, the
distribution of time since infection is similar across all ages, but
over time recent infections become relatively more common in
young adults.
These distributions results in substantial variation in the level of
misclassification by the BED test, if the PFP increases with time
since infection (scenario B in Figure 1). Figure 3 shows estimates of
e, in the different countries over time (Figure 3(a)) and across age-
BED Estimates of HIV Incidence
PLoS ONE | www.plosone.org 2 May 2009 | Volume 4 | Issue 5 | e5720Figure 1. The influence of time since infection on the proportion of BED test results that would be positive. The pattern over the first
year is informed by observational data, but pattern over the remaining time is uncertain and two hypothetical scenarios were used in our modelling
(scenarios A and B).
doi:10.1371/journal.pone.0005720.g001
Figure 2. Distributions of time-since-infection for the HIV-infected populations across six African countries (Kenya, Lesotho,
Mozambique, Nigeria, Uganda and Zambia) in (a) 1995 and (b) 2005; and across age-groups in Uganda in (c) 1995 and (d) 2005.
Categories are(from base upwards): ,4months (dark blue); ,1 y (light blue); ,4 y (cyan); ,8 y (green); ,12 y (yellow); ,16 y(orange); 16+y (dark red).
doi:10.1371/journal.pone.0005720.g002
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increases with time, especially in countries where the epidemic has
declined. The rate of increase is related to the timing of epidemic
spread, and varies between countries giving a range, in 2005, of
6% (Mozambique) to 17% (Uganda). Across age in 2005, the
misclassification rate is stable (5%) for 15–24 year-olds, and
sharply increases between ages 25–39 years (up to 30% in Uganda
and 7% in Lesotho). However, this pattern with respect to age is
dynamic, and the relative value of e between the different age-
groups also evolves over the course of the epidemic. The
corresponding graphs for BED response scenario A shows a
constant misclassification rate of 5%, as per the assumption.
The estimated incidence that would come from using the BED
test, corrected using a constant value of e~5% [14], is compared
with the Spectrum incidence rate (Figure S2). For scenario A (PFP
constant over time since infection) incidence is detected approx-
imately correctly in all settings. In contrast, for Scenario B (PFP
increases over time since infection), incidence is over-estimated in
the period 1995–2005 in most countries. The extent of the over-
estimate in 2005 is negligible in some countries (Lesotho and
Mozambique – though it increases later) and highest in Kenya (3-
times too high) and Uganda (5-times too high). Across countries,
the extent of the bias with respect to age is highly variable. In
general, the bias is modest in all settings among ages 15–29, but
increase sharply at older ages, and is greatest for the 35–39 years
age-group.
Figure 4 shows the relationship between trends in Spectrum and
BED estimates of incidence following instantaneous changes in the
incidence rate. For Uganda (a declining epidemic) and BED
response scenario A, Spectrum trends in incidence are only
roughly reflected in changes in the BED estimates (green line
poorly approximates diagonal grey line) (Figure 4(a)). In the ‘no-
change’ simulation (1.0 on the horizontal axis) the BED test falsely
indicates a reduction in incidence, which is generated by the
shifting distribution in time since infection among the infected
population. For Scenario B, the relationship between actual
changes in incidence and changes in the BED-estimates of
incidence shows only a weak positive correlation. For Zambia
and Mozambique (stable and growing epidemics, respectively), the
performance of the BED estimates using scenario A is good, with
no false detection of a trend in incidence and a close relationship
between actual trends in incidence and that recorded in the BED
test (Figure 4(b)). In Zambia and Mozambique there is a weak
correlation between actual trends in incidence trends and changes
in BED estimate using scenario B.
In stabilised epidemics, where our modelling indicates that
actual changes in incidence could be reliably recorded in the BED
estimates of incidence assuming scenario A, we calculated the
sample sizes required to record a statistically significant difference
in two cross-sectional sero-surveys. In these calculations, we
require 80% chance of detecting a statistically significant
difference in the proportion of recent infections in a two-sided
test at the 5% significance level. For Zambia, where the rate of
incidence is relatively high, sample sizes for each survey of
approximately 12,000 and 54,000 are required to detect a 50% or
25% reduction in incidence respectively, assuming BED response
function scenario A. For Nigeria, where the rate of incidence is
much lower, sample sizes of approximately 52,000 and 220,000
would be required to detect a 50% or 25% reduction in incidence,
assuming BED response function A. Sample sizes calculations
using scenario B were not calculated since trends in BED estimates
of incidence under these test properties could not be reliably
interpreted.
Discussion
Although it is widely recognised that the BED test can
misclassify old infections as recent, there has been renewed
confidence in using BED-derived estimate of incidence if a post-
assay analytic correction procedure is used [14,16]. However, for
this to work, the proportion of non-recent infection that the test
misclassifies (e) must be known. In this modelling exercise we have
found that if the chance of misclassification by the test does not
change over time, then empirical measurements of e can be used
universally, and corrected estimates of incidence will be accurate.
However, we also find that if the chance of misclassification by the
test increases for those with very advanced infections, then this
quantity will vary by place, over time and across age-groups. It has
Figure 3. Proportions of infections at least one year old that are misclassified by the BED test for six African countries, (a) over time
(ages 15–49), and (b) over age (in year 2005) using BED response scenario B (increasing proportion false positive: panels c & f). Lines
show: Kenya (red line and circles), Lesotho (blue line and squares), Mozambique (green line and plus-signs), Nigeria (pink link and triangles), Uganda
(black lines and diamonds), and Zambia (brown line and crosses). The lines are dotted after 2005, since Spectrum incidence were not calculated after
2005: these results are based on assuming incidence remains constant at 2005 levels.
doi:10.1371/journal.pone.0005720.g003
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results leads to substantial biases in ‘corrected’ estimates of
incidence [14,17]. Our modelling shows that comparisons of
incidence estimates within populations (over age, or factors
correlated with age such as marriage/widowhood), over time or
between populations may also be unreliable.
The exact nature of the relationship between misclassification
and time since infection is not known. There are observational
studies showing that individuals with low CD4 counts/high viral
loads are much more likely to be misclassified than infected
individuals with high CD4 counts/low viral loads [19,23,24,26].
Also, if the individuals with fully developed immune-responses that
are misclassified as recent live for longer than others, then
misclassification rates will also vary with time since infection
[23,28]. Moreover, the wide variation in the few empirical
measurements of e [13,14,17,18], the greater values measured in
Rwanda, Zambia, Uganda and Zimbabwe (where the epidemics
have stabilised/declined) than South Africa (where the epidemic
continues to grow) are consistent with the model predictions
assuming that PFP does increase with time since infection.
Furthermore, the empirical estimate of e in Uganda [19] and
the degree of apparent error in corrected BED estimate of
incidence in Uganda and Kenya [21,22], are also in close
quantitative agreement with our model predictions. Thus,
assuming that PFP is constant over time may not be safe, and
reported estimates of incidence should properly reflect the
uncertainty and potential for substantial error that would arise if
PFP increases with time since infection.
Even though the level of the incidence estimate may be biased,
it has been suggested that patterns with respect to age and time in
BED estimates may used to identify risk groups and track changes
in the epidemic. The BED test was recently used to identify groups
at highest risk in Uganda [21], and the pattern of incidence over
age was surprising: whilst these data suggested that the ages of
peak incidence for women (35–39 years: 3.5/100pyar) was older
than for men (30–34 years: 2.8/100pyar), other empirical data
from Uganda and other countries in sub-Saharan African [34,35],
show that typically the age-groups with the highest incidence rates
are ten years younger, and at older ages for men than women. The
authors of a South African BED study also comment that
incidence in older age-groups was surprisingly high [20]. In both
cases, it was speculated that this may be due to patterns of
Figure 4. The ability of the BED test to detect changes in incidence. The incidence change estimated in 2006 five years after an
instantaneous change in incidence by a factor 0.5, 0.75, 1.0, 1.25 or 1.5 (i.e. decreased by half, decreased by a quarter, no change, increased by a
quarter, increased by half), using the alternative BED response scenarios: scenario A (stable proportion false positive: green squares); and, scenario B
(increasing proportion false positive: red triangles). The analysis is repeated for incidence patterns representative of Uganda (a); Zambia (b); and,
Mozambique (c). Note that a factor of 1.0 indicates no change in incidence. The thick diagonal grey line shows the 1:1 relationship expected if the
BED estimate perfectly tracks changes in incidence.
doi:10.1371/journal.pone.0005720.g004
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surprising pattern of incidence over age may, in fact, be due
misclassification increasing with time infected.
We investigated the ability for the BED estimates of incidence to
detect actual changes in incidence and found that, as anticipated
by earlier observations [14], in some settings (e.g. Uganda and
Kenya) declines in BED estimates of incidence can be spuriously
generated by natural changes in the distribution of time-since-
infection in the infected populations. In other settings (e.g.
Zambia), we found that under certain assumptions about the
BED response function (scenario A), changes in the BED estimate
of incidence can reliably reflect changes in the actual incidence
rate. However, the ability to record statistically significant changes
in BED-estimates of incidence requires samples sizes much larger
than are routinely used in existing surveys [21,22,36] (e.g. samples
of ,50,000 individuals per sero-survey in Zambia for a 25%
reduction in incidence, and much more in settings with lower
incidence). Another study has shown that when the uncertainty in
any calibrating parameters is also considered, sample sizes of at
least 10,000 are required even to identify greater changes in high-
incidence settings (reviewed in [37]). Nonetheless, with a third
survey a test for trend across time could be applied that may lead
to smaller sample sizes being required in each survey. Official
guidelines for the BED test do highlight the importance of using
sufficiently large samples [16], but this poses substantial logistic
difficulties in many settings.
Our modelling did not consider that the BED response scenario
could also vary by sex, age, pregnancy status, or viral sub-types. All
of these would lead to further variation in e by place, time and age.
It has also been shown that the measured sensitivity and specificity
of the test over the first two years will depend on the distribution of
time since infection [38], meaning that the biases in estimates
could be even more varied than suggested here. We have not
directly considered the use anti-retroviral treatment in the model,
which can also lead to misclassification. While some national
population-based surveys that have applied BED have not done
this, future sero-surveys should identify those in treatment so that
they could be excluded from the analyses. If the exclusion is not
fully effective, treatment could introduce an additional time-
variable bias, creating an exaggerated version of scenario B
(Figure 1).
Our modelling supports empirical work showing the BED test
can be used successfully with a locally and recently measured value
of e [14,39]. However, we have also shown that the value of e
quickly becomes ‘out-of-date’, and cannot easily be transferred to
other settings. Thus, for reliable results, e should be measured for
each population in which the test is used. CD4 cell count data
could help to exclude some individuals with long-term infections
but, in addition to the logistical challenges of doing this, the
variability in CD4 counts within and between individuals [40]
would make such a correction technical involved and likely
incomplete. Unfortunately, using reported behavioural data to
exclude confirmed long-term infection (such as date of first positive
HIV test) is not likely to lead to sufficient improvements in
specificity, since testing rates in Africa are currently low [41].
The relationship between misclassification and time since
infection could be directly observed by applying the BED assay
(and other similar assays) to sera collected from individuals with
known durations of infection ranging from 0 to 20 years. In
addition, further immunological research may describe the
underlying causes for changes in antibody composition over time,
which could help inform the shape of the BED response function.
This would provide the basis for making better assumptions made
about the BED response function, enabling more reliable forms of
post hoc correction.
From our analysis, we conclude that the current use and
correction of BED test data could well lead to errors in
understanding current patterns and trends in incidence. Much
more work needs to be done to understand the test properties and
such work should draw on longitudinal data from long-term
cohort studies.
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